Answers are grounded in this paper and cite their sources.
Background: The human hepatitis B virus (HBV) is currently prevalent in 250 million people. Chronic hepatitis B (CHB) has been associated with cirrhosis, hepatocellular carcinoma (HCC), liver failure, and overall mortality. This study aimed to determine the prevalence of the hepatitis B virus, its genotype, mutations, and antiviral resistance in hemodialysis centers from the Gaza Strip, Palestine. Results: From the 273 HD patients participating in the study from the four HD centers in Gaza Strip, HBcAb was detected in 19 patients (6.96%), where HBsAg was detected in 12 patients (4.4%). HBV DNA was detected in 17 of the 19 positive HBcAb patients (89.47%); sequencing of the positive DNA by Sanger methods for the partial polymerase gene of HBV shows that genotype D is the only detected genotype where subgenotype D1 is the common (82.35%) followed by D2 (17.65%); Detection of reverse transcriptase antiviral resistance was done for the nucleotide analog (NUCs) Lamivudine, Adefovir, Entecavir, Tenofovir, and Telbivudine and all cases were sensitive to the mentioned antiviral. Neighbor-joining tree analysis was used to construct a phylogenetic tree with 130 reference strains with genotype D retrieved from GenBank. HBsAg positive patients had ALT and AST mean values higher than negative patients with a highly statistically significant relationship (p<0.01). Conclusion: Genotype D HBV is common in HD with emphasis on the significance of identifying genotype, mutation, and antiviral resistance among isolated positive samples because these elements are crucial to the progression of the illness, its severity, chronicity, and treatment response.
No takes yet. Share an insight, caveat, or question.
ElOttol et al. (2023) studied this question.